Adhd Signals
ADHD Brain Science: Dopamine, Norepinephrine, and Serotonin (Additudemag)
Summary: A crash course on the neurotransmitters implicated in ADHD and how new medications are targeting serotonin, a historically overlooked chemical in ADHD treatment. … Stimulant medications have focused almost exclusively on raising dopamine and norepinephrine levels in the brain.
Why it matters: This matters for Neurodiversity, ADHD, Autism, and AuDHD because it gives a concrete current signal to track: A crash course on the neurotransmitters implicated in ADHD and how new medications are targeting serotonin, a historically overlooked chemical in ADHD treatment.
Context: A crash course on the neurotransmitters implicated in ADHD and how new medications are targeting serotonin, a historically overlooked chemical in ADHD treatment. … Stimulant medications have focused almost exclusively on raising dopamine and norepinephrine levels in the brain.
"A crash course on the neurotransmitters implicated in ADHD and how new medications are targeting serotonin, a historically overlooked chemical in ADHD treatment. … Stimulant medications have focused almost exclusively on raising." — ADDITUDEMAG
Commentary: The immediate implication is operational rather than speculative: watch how this changes budgets, workflows, or risk assumptions over the next cycle.
Date: April 20, 2026 12:00 AM ET
URL: https://www.additudemag.com/adhd-brain-science-research/
AI Sentiment Score: Negative (66%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.ADHD Research News – CHADD (Chadd)
Summary: ### New ADHD research studies referenced in this week’s ADHD in the News: – Bach, P., et al. (2026). Prescription psychostimulants, atomoxetine and the risk of psychosis in adults with history of psychosis: A population-based cohort study. Translational Psychiatry,16(1), 226.
Why it matters: This matters for Neurodiversity, ADHD, Autism, and AuDHD because it gives a concrete current signal to track: ### New ADHD research studies referenced in this week’s ADHD in the News: – Bach, P., et al.
Context: ### New ADHD research studies referenced in this week’s ADHD in the News: – Bach, P., et al. (2026). Prescription psychostimulants, atomoxetine and the risk of psychosis in adults with history of psychosis: A population-based cohort study. Translational Psychiatry,16(1), 226.
"### New ADHD research studies referenced in this week’s ADHD in the News: – Bach, P., et al. (2026). **Prescription psychostimulants, atomoxetine and the risk of psychosis in adults with history of." — CHADD
Commentary: The immediate implication is operational rather than speculative: watch how this changes budgets, workflows, or risk assumptions over the next cycle.
Date: April 24, 2026 12:00 AM ET
URL: https://chadd.org/for-professionals/adhd-research-news/
AI Sentiment Score: Negative (80%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.ADHD symptom manifestation in adulthood: moving beyond … (Cambridge)
Summary: Adverse outcomes are higher in untreated cohorts (Shaw et al. Reference Shaw, Hodgkins, Caci, Young, Kahle, Woods and Arnold2012). Identification of adult ADHD is important for accessing treatment (Katzman et al. Reference Katzman, Bilkey, Chokka, Fallu and Klassen2017). …
Why it matters: This matters for Neurodiversity, ADHD, Autism, and AuDHD because it gives a concrete current signal to track: Adverse outcomes are higher in untreated cohorts (Shaw et al. Reference Shaw, Hodgkins, Caci, Young, Kahle, Woods and Arnold2012).
Context: Adverse outcomes are higher in untreated cohorts (Shaw et al. Reference Shaw, Hodgkins, Caci, Young, Kahle, Woods and Arnold2012). Identification of adult ADHD is important for accessing treatment (Katzman et al. Reference Katzman, Bilkey, Chokka, Fallu and Klassen2017). …
"Adverse outcomes are higher in untreated cohorts (Shaw et al. Reference Shaw, Hodgkins, Caci, Young, Kahle, Woods and Arnold2012). Identification of adult ADHD is important for accessing treatment (Katzman et al. Reference." — CAMBRIDGE
Commentary: The immediate implication is operational rather than speculative: watch how this changes budgets, workflows, or risk assumptions over the next cycle.
Date: April 21, 2026 12:00 AM ET
URL: https://www.cambridge.org/core/journals/irish-journal-of-psychological-medicine/article/adhd-symptom-manifestation-in-adulthood-moving-beyond-conceptualisations-of-inattention-and-hyperactivityimpulsivity/444EEC3AD2DA08FCCC1C3A0B1B41A488
AI Sentiment Score: Positive (66%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.ADHD Treatment Despite a History of Psychosis – ZI Mannheim (Zi-Mannheim.De)
Summary: # NewsNe# ADHD Treatment Despite a History of Psychosis: Study Finds No Increased Risk of RelapseapA new study conducted in collaboration with CIMH shows that medication for ADHD does not appear to increase the risk of relapse in people with a history of psychosis. … The findings of the current study challenge a widely held clinical assumption that ADHD medications should generally be avoided in people with psychosis.
Why it matters: This matters for Neurodiversity, ADHD, Autism, and AuDHD because it gives a concrete current signal to track: # NewsNe# ADHD Treatment Despite a History of Psychosis: Study Finds No Increased Risk of RelapseapA new study conducted in collaboration with CIMH shows that medication for ADHD does not appear to increase the risk of relapse in people with a history of psychosis.
Context: # NewsNe# ADHD Treatment Despite a History of Psychosis: Study Finds No Increased Risk of RelapseapA new study conducted in collaboration with CIMH shows that medication for ADHD does not appear to increase the risk of relapse in people with a history of psychosis. … The findings of the current study challenge a widely held clinical assumption that ADHD medications should generally be avoided in people with psychosis.
"# NewsNe# ADHD Treatment Despite a History of Psychosis: Study Finds No Increased Risk of RelapseapA new study conducted in collaboration with CIMH shows that medication for ADHD does not appear to." — ZI-MANNHEIM.DE
Commentary: The immediate implication is operational rather than speculative: watch how this changes budgets, workflows, or risk assumptions over the next cycle.
Date: April 22, 2026 12:00 AM ET
URL: https://www.zi-mannheim.de/institut/news-detail/adhd-treatment-despite-a-history-of-psychosis-study-finds-no-increased-risk-of-relapse.html
AI Sentiment Score: Negative (76%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.Post ID: 2f777158